Bronchiectasis
-
Adult bronchiectasis guidelines updated to reflect emerging evidence on disease identification and management
New bronchiectasis recommendations from the European Respiratory Society reflect a shift toward individualized, risk-based care, recognizing diverse inflammatory and microbiologic profiles. The guidelines emphasize early identification of high-risk patients, multidimensional assessment, and universal airway clearance training.
-
Patients with COPD, bronchiectasis experience sex-based disparities in care
Radmila Choate, PhD, MPH, and her team sought to capture “lived experiences in a way that helps clinicians recognize patterns that differ for women and men and adapt care more thoughtfully.”
-
Panel to introduce new CHEST North American bronchiectasis guidelines
Ashwin Basavaraj, MD, FCCP, will chair a Tuesday afternoon session summarizing CHEST’s North American bronchiectasis guidelines, their development process, and a case-based scenario for implementing their recommendations.
-
Bridging Specialties program tackles NTM pulmonary disease and bronchiectasis
CHEST launched Bridging Specialties®: Timely Diagnosis for NTM Pulmonary Disease and Bronchiectasis as a way for PCPs and pulmonologists to collaborate and provide earlier and accurate diagnoses.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
-
Brensocatib awaits FDA approval for bronchiectasis following ASPEN results
Experts Mark Metersky, MD, FCCP; Pamela J. McShane, MD; and Charles L. Daley, MD, FCCP, discuss the potential clinical implications of addressing inflammation in bronchiectasis—from reduced exacerbations and slowed decline in FEV to improved quality of life.
-
FDA grants clearance for SIMEOX 200 for patients with chronic lung disease
The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all age groups and 813 per 100,000 in the over 65 age group.1 A retrospective cohort study suggests the incidence of NCFB as ascertained from International…
